Alnylam preclinical data

In a mouse model of MI, Alnylam's anti-CCR2-siRNA-loaded nanoparticles reduced infarct size and the number of proinflammatory monocytes in the heart vs. small molecule inhibitors of CCR2. In a mouse ...